More than $100 Billion Opportunities in Active Pharmaceuticals Ingredients (APIs) Market Over the Next 6 Years
The research study on the active pharmaceutical ingredients (APIs) market – global outlook & forecast 2023-2028, recently published by Arizton Advisory & Intelligence, states that the market will grow at a CAGR of 6.67% during 2021-2027.
In recent years, APAC has dominated the global active pharmaceutical ingredients market. Some manufacturers in the market include Glenmark Lifesciences, Aurobindo Pharma, and Biocon. These vendors focus on capitalizing on their product portfolios that best suit the domestic requirements and international market.
Over the past decade, several companies have engaged in M&As to establish their presence in the market. M&As offer several benefits, such as better access to procuring raw materials, distribution, and R&D, and are primarily driven by consolidation. Companies focus on sustainability with a commitment to generate more value from fewer resources due to the highly competitive and volatile environment in the market. Several companies focus on turning environmental challenges and societal concerns into product innovations. Key players, such as Pfizer and Novartis, are involved in several ongoing green chemistry initiatives and sustainability partnerships with government bodies globally. Sustainability emerged as a fundamental strategic approach for vendors to gain a competitive edge in the market.
Active Pharmaceutical Ingredients (API) Market Report Scope
|Market Size (2028)||USD 312.37 Billion|
|Market Size (2022)||USD 212.07 Billion|
|Market Segmentation||Molecule Type, Therapy Area, Manufacturers Type, Brand, Potency, and Geography|
|Geographic Analysis||North America, Europe, APAC, Latin America, and Middle East & Africa|
Increased API Outsourcing Operations Driving the Market Growth
The growth of API outsourcing operations offers several benefits to the pharmaceutical industry. Outsourcing operations can help to reduce costs. The costs associated with production are reduced, as the costs associated with production are shared between the supplier and the pharmaceutical company as the production of APIs is outsourced to third-party suppliers. Furthermore, outsourcing operations can also help to reduce the risks associated with production. As the production of APIs is outsourced to a third-party supplier, the pharmaceutical company does not have to bear risks related to production, as these are shared between the supplier and the pharmaceutical company. Outsourcing operations can also help to improve the quality of APIs. Suppliers can ensure the quality of APIs as suppliers can use the latest technologies and techniques to ensure the quality of APIs.
Buy the Report Now: https://www.arizton.com/market-reports/active-pharmaceutical-ingredients-market
The global active pharmaceutical ingredients (API) market by molecule type is classified as large and small. This differentiation not only considers the size of the molecule but also how the molecules are made, their behavior, drug delivery, and mode of delivery. A small molecule API refers to an organic compound with a size of about 1 nm, which assists in regulating biological processes. Small molecules may be orally delivered, and the body is most likely to consume them. They possess the characteristics of rapid infusibility due to their small size, which enables them to reach the intercellular site of action. Small molecules have long been the basis for drug development. They are easily digested or absorbed into the bloodstream. The cardiovascular therapy area dominated the global active pharmaceutical ingredients (API) market, accounting for a share of over 19% in 2022. Cardiovascular APIs are manufactured by companies involved in drug manufacturing for cardiovascular diseases. Manufacturers producing hypertensive drugs for people with high blood pressure drive the market’s growth. Cardiovascular disease is a significant cause of death and disability worldwide and is a major medical research and development focus. Pharmaceutical interventions are an essential part of treatment for cardiovascular conditions, particularly when managing risk factors such as high blood pressure, high cholesterol, and diabetes. APIs are used to create medicines targeting specific aspects of the condition to achieve effective cardiovascular therapy.
Oncology therapy holds a significant share of the global active pharmaceutical ingredients (API) market. It is driven by the increasing incidence of cancer cases across the globe due to alarming environmental changes, the adoption of a sedentary lifestyle, and rising awareness amongst the population. Improved access to cancer care, including cancer prevention, screening treatment, and follow-up care, are some of the significant factors contributing to the growth of the oncology therapy market. New targeted therapies for cancer are currently being focused upon in anti-cancer drug development.
- 1hr of free analyst discussion
- 10% of customization
Why Should You Buy this Active Pharmaceutical Ingredients Market Report?
- This study provides an in-depth overview of the API market, including its size, development potential, and important trends.
- This research includes thorough information on the API market’s top players, strategies, and products.
- This research will aid in your decision-making so that you can decide whether to enter the API industry or develop your current activities.
- Additionally, this study will assist you in locating and assessing prospective business opportunities in the API industry.
- This report analysis will inform you of the most recent changes in the API market.
To Get the Benefit of Our Free Report Customization Service, Send Your Enquiry Here – https://www.arizton.com/customize-report/3836
Key Company Profiles
- Boehringer Ingelheim
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Merck KGaA
- Sun Pharmaceutical Industries
- Albemarle Corporation
- Aurobindo Pharma
- BASF Corporation
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceuticals Industries
- F. Hoffmann-La Roche
- GLENMARK PHARMACEUTICALS LTD.
- Shenzhen Hepalink Pharmaceutical Group
- Molecule Type: Small Molecule/ Chemical API and Large Molecule/ Biological API
- Therapy Area: Cardiovascular, Oncology, Neurology, Anti-infectives, Endocrinology, Pulmonology, and Others
- Manufacturers Type: Captive and Merchant
- Brand: Patented/ Innovative API and Generic API
- Potency: Non-potent API and Highly Potent API
- Geography: North America, Europe, APAC, Latin America, and Middle East & Africa
Explore more healthcare reports: https://www.arizton.com/market-reports/category/healthcare-lifesciences
Check Out Some of the Top Selling Research Reports:
IV and Oral Iron Drugs Market – Global Outlook and Forecast 2021-2026
Biosimilar Contract Manufacturing Market – Global Outlook & Forecast 2022-2027
Immunotherapy Drugs Market – Global Outlook & Forecast 2021-2026
Vaccine Contract Manufacturing Market – Global Outlook and Forecast 2021-2026
Key Questions Answered in the Report:
- How big is the active pharmaceutical ingredients (API) market?
- What is the growth rate of the global active pharmaceutical ingredients (API) market?
- What are the growing trends in the active pharmaceutical ingredients (API) market?
- Which region holds the most significant global active pharmaceutical ingredients (API) market share?
- Who are the key players in the global active pharmaceutical ingredients (API) market?
Arizton Expertise in the Healthcare Industry
Arizton offers syndicate and custom market intelligence & competitive intelligence solutions across MedTech, pharmaceuticals, and life sciences & biotechnology markets within the healthcare industry. Arizton’s healthcare vertical provides unbiased research and evidence-based analysis to support business decisions and comprehensive end-to-end solutions to its customers, covering all dimensions of the healthcare value chain. We track various devices (equipment, implants, and hospital supplies) and drugs (patented, generic, & OTC) across North America, Europe, APAC, Latin America, and the Middle East & Africa regions. The healthcare reports provide historical and forecast data for 20+ key countries worldwide. We track product approvals/launches, M&A activities, and collaboration/partnership activities among pharma/biotech, medical device, and life sciences companies. Our pharmaceutical portfolio tracks 15+ therapy areas with a significant focus on immunology, oncology, rare & genetic diseases, dermatology, and metabolic diseases. Our medical devices and life sciences portfolio covers in-vitro diagnostics, healthcare IT, patient monitoring, cardiovascular devices, medical imaging, personal protective equipment, clinical laboratory services, and CMO/CDMO services.
Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.
Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Why Arizton Research Reports?
100% Customer Satisfaction
24×7 availability – we are always there when you need us.
200+ Fortune 500 Companies trust Arizton’s report.
80% of our reports are exclusive and first in the industry.
100% more data and analysis.
1000+ reports published to date.